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Infants and Children: a Systematic Review and Meta-analysis
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Magnus Domello¨f, #Nicholas Embleton, Natasˇa Fidler Mis, yyJessie M. Hulst,
zzFlavia Indrio, §§jjjjAlexandre Lapillonne, Walter Mihatsch, ##Christian Molgaard,
yyyzzzJohannes van Goudoever, and §§§Mary Fewtrell, ESPGHAN Committee on Nutrition
ABSTRACT
The aim of the present article was to perform a systematic review with meta-
analysis of available scientific evidence regarding the role of different
intravenous lipid emulsions (ILE) in the pathogenesis of cholestasis and
parenteral nutrition–associated liver disease. A systematic review of the
literature (up to March 2015) identified 23 randomized controlled trials
(RCTs). Of these, 17 were performed in preterm infants or critically ill
neonates with a short duration of intervention, 2 in older children with short-
term use (following surgery or bone marrow transplantation), 1 in neonates
with long-term use, and 3 in infants and children receiving long-term
parenteral nutrition (PN). Meta-analysis showed no differences in the rate
of cholestasis or bilirubin levels associated with short-term use of different
ILEs. Because of high heterogeneity of the long-term studies no meta-
analysis could be performed. Available studies found that the use of
multicomponent fish oil (FO)-containing ILE compared with pure soya
bean oil (SO), ILE-reduced liver enzymes, and bilirubin levels in nonchole-
static children on long-term PN and one other RCT found that FO-based
ILE-reversed cholestasis in a proportion of patients. The ESPGHAN Com-
mittee on Nutrition concludes that there is no evidence of a difference in
rates of cholestasis or bilirubin levels between different ILE for short-term
use in neonates. The use of multicomponent FO-containing ILE may
contribute to a decrease in total bilirubin levels in children with IF on
What Is Known
 There is evidence that intravenous lipid emulsions
(ILE) play a role in the pathogenesis of cholestasis and
parenteral nutrition–associated liver disease.
 A number of trials have suggested that novel fish oil–
containing ILE could have a beneficial effect on choles-
tasis and parenteral nutrition–associated liver disease.
What Is New
 The present systematic review identified 23 random-
ized controlled trials, which evaluated the effect of
different ILEs on cholestasis.
 Meta-analysis showed no differences in the rate of
cholestasis or bilirubin levels associated with short-
term use of different ILE formulations in preterm
infants, neonates, and children.
 Although quality data are lacking there is some
evidence that the use of multicomponent fish oil–
containing ILE may contribute to a decrease in total
bilirubin levels in children with intestinal failure on
prolonged parenteral nutrition.
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prolonged PN. Well-designed RCTs are, however, lacking and long-term
effects have not been determined.
Key Words: children, fish oil, infants, lipids, medium-chain triglycerides,
neonates, olive oil, soya bean oil
(JPGN 2016;62: 776–792)
D uring the last 3 decades, parenteral nutrition (PN) has beenincreasingly used to improve nutritional status in paediatric
patients ranging from premature infants not fully tolerating enteral
nutrition to children with intestinal failure (IF). IF is defined as the
inability of the gut to absorb the minimal fluids and energy
requirements necessary to sustain life and growth (1). Normal or
catch-up growth and long-term survival have become possible in
children with chronic IF who depend on total or (more often)
complementary PN (2–5). Along with technological advances
and improvements in clinical understanding, and the widespread
adoption of guidelines provided by expert teams (6), the quality of
paediatric PN has dramatically improved. PN-associated liver disease
(PNALD), however, has long been considered as one of the most
frequent and life-threatening complications of PN, especially in
children with chronic IF (7,8). PNALD is defined as cholestasis
occurring in the setting of PN, if other specific causes of liver injury
have been excluded. Cholestasis is usually defined as an elevated
conjugated serum bilirubin (2 mg/dL [34.2 mmol/L]) (9). Overall
cholestasis affects a large number of patients receiving PN; it may
develop in 40% to 60% of infants (10) and up to 85% of neonates (11)
who require long-term PN. Moreover, evidence of liver dysfunction
may occur as early as 14 days after initiating PN in neonates (12).
The term IF-associated liver disease (IFALD) (13,14), often
used interchangeably with PNALD, is a broader term including
causes other than PN such as underlying disease, massive intestinal
resection (15), sepsis (16,17), and absence of enteral feeding (10).
Because the focus of the present article is on the role of intravenous
lipid emulsions (ILE) we will use the term PNALD.
Risk factors for PNALD are related to many factors, but are
particularly associated with individual PN constituents, whether as
deficiencies, excesses, or toxicity (10). The possible toxicity of ILE,
in particular, is a focus of concern. Lipids are recognized as an
indispensable component of non-protein energy intake in patients
receiving PN. In addition to their high caloric value and low
osmolality, the use of ILE also prevents the complications of using
glucose as the sole non-protein energy source, including essential
fatty acid deficiency, hyperglycaemia, and hepatic steatosis (18,19).
A possible role of ILE in the pathogenesis of cholestasis was
suggested by several studies (20,21).
Because of the recent availability of a new generation of ILE
and promising results in the prevention and treatment of PNALD,
the aim of the present article is to summarize the scientific evidence
regarding the role of different ILE in the pathogenesis of cholestasis
and PNALD and to perform a systematic review with, where
appropriate, a meta-analysis on the effect of different types of
ILE on cholestasis and PNALD.
INTRAVENOUS LIPID EMULSIONS
The first ILE was introduced in the early 1960s and was
considered a major breakthrough in PN care. The first commercially
available product consisted of the long-chain triglyceride (LCT)
soya bean oil (SO) (22). These ILE contained small amounts of n-3
fatty acids and high amounts of n-6 essential fatty acids, mostly
linoleic acid, whereas the remaining profile mostly included
saturated fatty acids such as palmitic and stearic, in descending con-
centrations (22). In the late 1980s, mixed preparations containing
50% medium-chain triglycerides (MCT) and 50% soya-based LCT
became available (MCT/SO). MCT were long advocated as a
superior substrate for PN use, because they are hydrolysed more
quickly than LCT and possess many unique physiochemical and
metabolic properties making them theoretically advantageous more
than their LCT counterparts. These advantages include preferential
lipoprotein lipase hydrolysis, non–carnitine-dependent metab-
olism, and rapid oxidation (23). In the late 1990s, a new olive
oil (OO)/SO lipid (OO/SO) emulsion (OO:SO¼ 4:1) with lower
(20% vs 60%) amounts of polyunsaturated fatty acid (PUFA), a
high amount of monounsaturated oleic acid, and higher vitamin E
content started to be used in patients on long-term PN (24–26). The
potential advantages of OO/SO ILE are to decrease the risks related
to an excessive intake of PUFAs such as increased peroxidation and
also to decrease the phytosterol load (27,28).
More recently fish oil (FO) has become available, either
alone or in combination with other oils. FO has several theoretical
advantages, including a high concentration of added a-tocopherol
(4- to 8-fold the amount in SO), and no phytosterols. Moreover, FO
is a rich source of docosahexaenoic acid (DHA), which is important
for neurodevelopment and visual function, and also a source of
eicosapentaenoic acid (EPA). EPA has been shown to favourably
modulate inflammatory pathways, both directly by decreasing the
production of pro-inflammatory cytokines and indirectly by an
increase in secretion of interleukin-10, an anti-inflammatory cyto-
kine, by hepatic macrophages (29). Furthermore, both DHA and
EPA serve as precursors of inflammation-resolving mediators (ie,
resolvins and protectins) (30). Theoretically high levels of EPA
may, however, prolong bleeding time and increase LDL cholesterol
levels, but clinical importance of these effects is unclear (31). In
animal models, FO delivered intravenously improves biliary flow
and decreases cholestasis (32), whereas it upregulates bile acid
transport mechanisms (33). It also reduces de novo lipogenesis,
stimulates b-oxidation, and decreases hepatic steatosis (34,35).
The characteristics of widely used commercially available
ILE are presented in Table 1.
MECHANISMS OF PNALD PATHOGENESIS
Various mechanisms have been proposed for the possible
role of ILE in PNALD, including modulation of oxidative stress and
inflammation (by peroxidation of PUFAs and differences in a-
tocopherol content), competition of transport (by differences in
phytosterol content), and by differences in lipid clearance (13,40).
Oxidative Stress
Excessive intake of linoleic acid, which is converted to
arachidonic acid, a precursor of proinflammatory agents (such as
tumour necrosis factor-a, interleukin-6, platelet activating factor,
and adhesion molecules), may have adverse effects on the liver
causing chronic inflammation, which could consequently lead to
liver cholestasis and fibrosis (29,36,41,42). PUFAs such as linoleic
acid can undergo peroxidation causing the production of lipid
peroxides, unstable molecules that can trigger chain reactions
resulting in inactivation of enzymes, proteins, and other elements
necessary for the viability of cells (22,43–45). This oxidative stress
is considered to be one of the possible causes of liver toxicity
resulting from lipids. In animal models, reactive oxygen species
increased during oxidative stress leading to decreased bile pro-
duction and contributing to cholestasis (46). In addition, low levels
of the antioxidant a-tocopherol in SO ILE (47) can modulate the
risk of oxidative stress (45,48); therefore, some lipid emulsions
contain added a-tocopherol (24). Accordingly, new generations of
ILE aim to provide n-3 and to reduce n-6 fatty acids load while
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enhancing a-tocopherol intake (40). Levels of a-tocopherol in
different ILE are presented in Table 1.
Phytosterols
Another major concern is related to plant sterols (PS), also
called phytosterols. PS are steroid alcohols which belong to plant
cell membranes, similar to cholesterol in mammals. PS have a
striking structural similarity to bile acids. Conventional SO ILEs
contain significant quantities of PS and their long-term use leads to
a progressive increase in PS content in human cell membranes and
plasma lipoproteins (27). Enterally, PS are poorly absorbed by the
human intestine, but their blood concentrations are closely associ-
ated with cholestasis in children and adults (49–53). PS have been
shown to reduce bile acid secretion in rats and to inhibit secretory
function in isolated rat hepatocytes (54). The mechanism leading to
cholestasis is thought to be the antagonism of nuclear farnesoid X
receptor (FXR) which regulates bile excretion via the multidrug
resistance transporter 2, responsible for the transport of bile
components out of the hepatocyte (55). Multidrug resistance
transporter 2–deficient mice develop cholestasis (56) and mice
lacking the FXR are exposed to bile acid liver injury (57), whereas
treatment with an FXR agonist has shown a hepatoprotective effect
in a rat model of intrahepatic and extrahepatic cholestasis (58).
Furthermore, there is evidence presented from animal models that
total PN suppresses both bile acid production and hepatocyte
export (bile acid–induced bile salt export pump) leading to intra-
hepatic bile acid accumulation, and PS can cause inhibition of bile
acid–induced bile salt export pump expression (59). Information
available in the literature related to PS concentrations in ILE is
scarce; a study which compared PS concentrations in 8 commonly
used parenteral ILE demonstrated that concentrations of the var-
ious steroidal compounds varied greatly between the ILE, with the
highest levels found in SO ILE (Table 1) (27). This was confirmed
in a recent study in premature infants comparing an SO ILE
and multicomponent FO-containing ILE (SMOFlipid; Fresenius
Kabi, Germany—SO, MCT, olive, and fish oil) (37). It has,
however, recently been shown in piglet model that the difference
in cholestasis and liver injury among novel ILE, especially for
the group receiving multicomponent FO-containing ILE, were
only weakly correlated with plasma and hepatic PS content
suggesting that other components could influence liver injury
(59). Savini et al measured PS in preterm infants receiving different
types of ILE and found that PS serum levels were positively
correlated with PS intake (60). Cholestasis was, however, rare
and there was no difference in the liver function tests between
groups (60).
Activation of the Reticuloendothelial System
Although the metabolism of the oxidized fraction of the ILE
is relatively well known, far less understood is the destiny of the
nonoxidized fraction, which is sequestered by the reticuloendothe-
lial cells (RECs) in the liver (ie, Kupffer cells) and also by the
spleen, bone marrow, and lungs. In children, chronic administration
of ILE may overload REC and induce their acute or chronic
activation leading to hematologic disorders, accompanied by liver
dysfunction and cholestasis (61,62). In a rat model, ILE infusion
resulted in downregulated hepatic lipase activity and fat vacuoles in
Kupffer cells and hepatocytes, with morphological signs of
increased Kupffer cell activity, suggesting that ILE may activate
macrophages (63). In a mouse model, total PN was shown to reduce
the number of hepatic REC and to impair their function, resulting in
poor survival after intraportal bacterial challenge (64). CD14 and
toll-like receptor 4/MD-2 expression both showed significant
reductions (64). Some authors have hypothesized that intestinal
injury with increased intestinal permeability combined with admin-
istration of PN promote lipopolysaccharide-toll-like receptor 4
signalling-dependent Kupffer cell activation as an early event in
the pathogenesis of IFALD/PNALD (65). No relation between
IFALD, liver REC, and ILE has, however, yet been established
in humans.
TABLE 1. Characteristics of commercially available intravenous lipid emulsions used in reported randomized controlled trials (27,36–39)
Intralipid 20% ClinOleic 20% Lipofundin 20% SMOFlipid 20% Omegaven 10%
Abbreviation SO OO/SO MCT/SO multicomponent FO-containing FO
Year of introduction 1960s 1990s 1980s 2000s 1990s
Oil source, %
Soya bean 100 20 50 30 0
MCT 0 0 50 30 0
Olive 0 80 0 25 0
Fish 0 0 0 15 100
Fatty acids (% of total fatty acid)
Linoleic acid 53 18.7 29.1 37.2 4.4
Arachidonic acid 0.1 0.5 0.2 1.0 2.1
a-Linolenic acid 8 2.3 4.5 4.7 1.8
Eicosapentaenoic acid 0 0 0 4.7 19.2
Docosahexaenoic acid 0 0 0 4.4 12.1
n-6:n-3 ratio 7:1 9:1 7:1 2.5:1 1:8
Phytosterols (mg/L) based
on Angsten et al (39)
 34833 237 8 NA 47.6 0
Phytosterols (mg/L) based
on Xu et al (27)y
439.07 5.72 274.38 2.60 278.14 5.09 207 No phytosterols,
squalene 26.7 mg/L
a-Tocopherol (mg/L) 38 32 85 20 200 150–296
FO, fish oil; MCT, medium-chain triglycerides; OO, olive oil; SO, soya bean oil.
Data in the table are the mean value when an interval is given from the manufacturer (39).
y Independently evaluated concentration of 9 different phytosterols and sqalene (27).
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ROLE OF DIFFERENT ILE IN THE
PATHOGENESIS OF PNALD
ILE (10% vs 20%)
There are clinically significant differences in commercially
available 10% and 20% lipid emulsions, especially in their phos-
pholipid content; phospholipid/triglyceride ratio is higher in 10%
lipid ILE compared with 20% (66). Administration of 20% ILE
leads to significantly faster triglyceride clearance compared to 10%
ILE (67,68). Therefore, in most paediatric patients, only 20%
emulsions are used (69). Infants who received 10% ILE had
lipoprotein X–like particles in the low-density lipoprotein fraction,
which has previously been shown to be associated with cholestasis
(67). There is currently no evidence suggesting that different lipid
concentrations have an influence on cholestasis.
Dose Reduction
With the aim of preventing or treating cholestasis associated
with PN, some centres have attempted to modify lipid adminis-
tration by reducing the amount of lipid (70), cycling PN (71,72), or
temporarily completely removing lipids from PN in children on
prolonged PN (21,73) based on the assumption that a dose of 1
g  kg1  day1 or less may be effective in preventing PN-associated
cholestasis (PNAC) in both infants and children (11,21,74–76). A
small, randomized controlled trial (RCT) performed by Rollins et al
(77) found that reduction of the dose of SO ILE (1 g  kg1  day1 vs
standard dose 3 g  kg1  day1) lowered the conjugated bilirubin in
28 neonates who underwent surgery and who were on PN for at least
4 weeks (77). In contrast, a recently published retrospective study
failed to demonstrate that reduction of SO ILE to 1 g  kg1  day1
could delay the onset of cholestasis in 61 neonates (78). Moreover,
although there is some evidence that lipid restriction may be
beneficial and appropriate for patients with PNALD, the unknown
long-term effects on growth and neurodevelopment remain a con-
cern especially in premature infants (77).
Source of ILE
There is emerging evidence that the lipid source in ILE may
have a role in PNALD. Several case-control studies have reported
efficacy of FO as monotherapy (1 g/kg) in the treatment of PNALD
in infants and children (79–88). Similarly, resolution of cholestasis
was also found when multicomponent FO-containing ILE were
introduced (89,90). These promising new results elicited numerous
review articles and recommendations from different authorities on
which ILE should be used (13,38,91). Although this emerging data
suggest that lipid source could have a role in the prevention/
treatment of cholestasis, a comprehensive assessment of available
data is lacking. The aim of the present study is to perform a
systematic review of the available RCT on the role of different
ILE in the pathogenesis of cholestasis and PNALD in infants
and children.
MATERIALS AND METHODS
A systematic review of the literature using defined search
criteria was performed. A PubMed, EMBASE, and Cochrane
Central Register of Controlled Trials CENTRAL search up to
March 2015 was conducted. The following key terms were used
(words in the title or abstract of the manuscript): (‘‘lipid’’ OR ‘‘fat’’
OR ‘‘fatty acid’’ OR ‘‘oil’’) AND (‘‘parenteral’’ OR ‘‘intravenous’’
OR ‘‘infusion’’) AND (‘‘liver disease’’ OR ‘‘parenteral nutrition–
associated liver disease’’ OR ‘‘intestinal failure associated
liver disease’’ OR ‘‘liver disease’’ OR ‘‘cholestasis’’ OR ‘‘liver
enzymes’’ OR ‘‘bilirubin’’). The searches were limited to human
studies. An age filter to restrict the search to children (0–18 years)
and a filter for clinical studies were applied. The search was limited
to English language manuscripts and only published data
were considered. The reference lists of identified studies and key
review articles, including previously published reviews, were also
searched.
The primary outcome measure was the incidence of choles-
tasis defined as an elevated serum conjugated bilirubin 2 mg/dL
(34.2 mmol/L). Secondary outcomes were the levels of total and
conjugated bilirubin and liver enzymes (alanine transaminase
[ALT], aspartate transaminase [AST], alkaline phosphatase
[ALP], and g-glutamyltransferase [GGT]) after the use of ILE.
Studies were included if theymet all of the following criteria:
RCT design in infants and children who needed PN and received
parenteral lipid emulsion. No restriction on the dose or duration of
administration of lipid infusion was applied. Studies with other
designs (cohort studies, case series, case reports) were not included
in the analysis.
The level of evidence for selected studies was graded using
the Oxford Centre for Evidence-Based Medicine ‘‘Levels of
Evidence’’ methodology and disagreements were resolved by
discussion (92).
The data were analysed using Review Manager (RevMan)
version 5.3. The primary outcome (binary measure) was presented
as the risk of event (cholestasis) in experimental and control groups.
Secondary outcomes were continuous and were given as the mean
with standard deviation (SD). When data were presented as the
standard error of the mean, the SD was recalculated. If data were
presented as a median with the range, the authors were contacted to
provide us with the mean values and SD. Data that were reported
only as median values and no mean values were provided by the
authors (93) were not included in the analysis due to nonsymme-
trical distribution of the median.
In order to avoid heterogeneity, secondary outcomemeasures
were levels reported at the end of the study but at a maximum of
14 days (range 6–14 days). Cholestasis rate was taken into account
when reported although the time varied between studies (the longest
follow-up was 6 weeks). Only studies those used SO ILE as control
were included. Subgroup analysis was performed for specific
experimental ILE (OO/SO and multicomponent FO-containing
ILE).
Heterogeneity of the data was tested by visual assessment of
the forest plot and by using the I2 statistic in which levels of more
than 50% were considered as showing substantial heterogeneity.
RESULTS
Search Results
Twenty-three of 493 potential studies on the effects of
parenteral lipid emulsions on clinical outcomes met our predefined
inclusion criteria. A flow chart of the search results is provided in
Figure 1. Included studies were divided into 3 groups based on the
age of participants and duration of the study: neonates including
premature infants—short-term and long-term use, short-term use in
older infants and children; and long-term use (defined as 4 weeks
of PN) in infants and children.
Evaluation of Identified RCTs
Characteristics of included studies are reported in the supple-
mentary table (http://links.lww.com/MPG/A610. Seventeen studies
were performed in premature infants, 2 studies in older children
(>1 year of age) on short-term PN, 3 studies in infants and children
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(>1 month of age) on long-term PN (longer than 4 weeks), and 1
study in neonates on long-term PN.
From all the available studies meta-analysis could be per-
formed only in the preterm infants and neonates who were on short-
term PN. Overall, 11 studies reported at least 1 outcome, which was
used in the meta-analysis (37,60,93–101); all these studies used SO
ILE as a comparison. The meta-analysis did not include 5 studies
(102–106), which reported no exact values for tested parameters
and 1 study in which SO ILE was not used as a comparison (107).
Overall 11 studies reported incidence of the cholestasis at baseline
(93,95–103,107) from which 6 studies included only preterm
infants/neonates with cholestasis at the baseline (93,96–100).
Neonates Including Preterm Infants
Short-Term Use in Neonates Including Preterm
Infants
There were 17 RCT in total, which reported the influence of
ILE on bilirubin or liver enzymes in preterm infants or critically ill
neonates (Table 2). Six studies included children who had choles-
tasis at the time of the study (93,96–100). Only 2 studies deter-
mined bilirubin levels as a primary endpoint (105,106). Duration of
the intervention was short (median/mean duration 3–27 days).
OO/SO Versus SO ILE
Six studies examined the difference between OO/SO (20%
ClinOleic; Baxter, France) and SO (20% Intralipid; Fresenius Kabi,
Germany) ILE (95–97,101–103). Five studies were performed in
preterm infants; 4 studies found no difference in the bilirubin and/or
liver enzymes between groups (95,97,102). The largest study,
however, found significantly lower direct bilirubin 7 days after
intervention with OO/SO ILE, although there was no difference in
total bilirubin and liver enzymes (101). A study performed in
critically ill neonates found lower levels of GGT in children
who received OO/SO ILE (103).
MCT/SO Versus SO ILE
Two studies compared short-term use of SO (20% Intralipid)
versus MCT/SO-based (20% Lipofundin; B. Braun, Germany)
emulsions with no significant difference between interventions
(105,106).
None of the mentioned studies were suitable for meta-
analysis because there were no reported values for bilirubin levels
or liver enzymes.
Multicomponent FO-Containing (SO, MCT, OO, and FO)
Versus SO ILE
Six studies compared multicomponent FO-containing ILE, a
physical mixture of 30% SO, 30% MCT, 25% olive oil, and 15%
FO (SMOFlipid 20%) to SO (20% Intralipid) emulsion
(37,93,94,98–100).
Two studies found a significantly greater decrease in bilir-
ubin levels in the multicomponent FO-containing ILE group
(98,99), whereas a third one found lower GGT in the multicompo-
nent FO-containing ILE group, but no difference in bilirubin levels
(100). Three studies found no difference in the cholestasis rate
between groups (37,93,94).
Multicomponent FO-Containing (SO, MCT, FO) Versus
MCT/SO ILE
One small pilot study compared a mixture of 10% FO, 50%
MCT, and 40% SO to MCT/SO ILE and found no difference in total
bilirubin levels at the end of intervention and 6 weeks after the
intervention between groups (107). Because the present study did not
use SO ILE as a comparison it was not included into the meta-analysis.
Comparison of Different ILEs
The largest study included 144 premature infants randomized
into 5 arms (SO based [20% Intralipid], MCT/SO based [20%
Lipofundin], multicomponent FO-containing ILE [SO, MCT, and
FO] [20% Lipidem; B. Braun, Germany], OO/SO [20% ClinOleic],
and multicomponent FO-containing ILE [SMOFlipid 20%]) and
found no difference in bilirubin levels and liver enzymes between
groups (60). Unfortunately, as the present study presented outcome
values only 6 weeks after the introduction of ILE, it could not be
included into meta-analysis for secondary outcomes.
Meta-Analysis
Primary Outcome
Six studies reported on the incidence of cholestasis at the end
of the study (37,60,93,94,101,104). Pooled meta-analysis found no
difference in incidence in any experimental mixed ILE compared to
solely SO ILE (Fig. 2). The study by Pawlik et al (104) was not
included in the analysis due to the control group (which was not SO
ILE); the present study tested mixed FO-containing ILE (50%
OO/SO ILE [20% ClinOleic] þ 50% FO ILE [10% Omegaven])
compared to OO/SO ILE (20% ClinOleic) and found a significantly
higher incidence of cholestasis in the group who received OO/SO
ILE compared to multicomponent FO-containing ILE (320/70 vs
3/60; P¼ 0.001).
Secondary Outcomes Related to the Liver
All studies included in the meta-analysis reported total
bilirubin levels 6 to 14 days after the intervention (57,92–100)
and found no difference in overall effect and subgroup analysis
Total 491 records identified through
PubMed and Cochrane library
2 additional records identified
through reference list search
493 abstracts screened
436 excluded based on abstract
57 full text articles
23 assessed for eligibility
36 full text article excluded:
- 15 no RCT
- 7 retrospective study
- 5 case series
- 7 no liver outcome
- 1 included adult patients
Included RCTs:
- 17 in preterm neonates
- 2 in older children on short term PN
- 3 in infants and children on long term PN
- 1 in neonates on long term PN
FIGURE 1. Flow chart of search results. PN, parenteral nutrition; RCT,
randomized controlled trial.
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(Fig. 3). Similarly, no difference was found for conjugated bilirubin
assessed by 5 studies (37,95,96,98,101), ALP assessed by 4 studies
(96,97,100,101), and GGT assessed by 6 studies (95–98,100,101)
(Figs. 4–6). AST was assessed by 4 studies (37,96,97,101) (Fig. 7).
ALT was assessed by 8 studies (37,93,95–98,100,101); however,
due to high heterogeneity 1 study (97) was excluded from the meta-
analysis. Overall results and separate results for OO/SO ILE and
multicomponent FO-containing ILE found no difference comparing
to solely SO ILE (Fig. 8).
Long-Term Use in Neonates
Only 1 RCT (108) evaluated the use of FO ILE (10%
Omegaven) compared to SO ILE (20% Intralipid) on cholestasis
incidence in young neonates who required long-term (more than 4
weeks) PN. Unfortunately, due to the low incidence of cholestasis,
the study was terminated prematurely. Overall 19 neonates were
included and the study failed to demonstrate any difference in direct
bilirubin and liver function tests between groups (Table 3).
Infants and Children
Characteristics of included studies are reported in the supple-
mentary table (http://links.lww.com/MPG/A610. Two studies were
performed in older children (>1 year of age) on short-term PN and
3 studies in older infants or children (>1 month of age) on long-term
PN (longer than 4 weeks).
Children With Short-Term PN
Two studies evaluated the safety and efficacy of different
ILE in children older than 1 year of age (Table 4) (111,112). None
of the studies evaluated the influence of different ILE on liver
function tests or bilirubin levels as a primary outcome measure, and
none reported cholestasis rate. One study was performed in children
after abdominal/oesophageal surgery (111) comparing MCT/SO
(10% Lipofundin MCT/SO) versus SO ILE (10% Lipofundin S) and
reported a decrease in bilirubin levels in MCT/SO ILE, whereas in
the SO group concentrations remained elevated (108). Another
study included children after bone marrow transplantation and
compared MCT/SO (20% Lipofundin) and OO/SO ILE (20%
ClinOleic) (112). That study found no difference between groups
in bilirubin levels and liver function tests.
Infants and Children With Long-Term PN
There are 3 RCTs which examined long-term administration
of ILE (Table 3). Two studies were performed in a single centre
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FIGURE 2. Effect of mixed intravenous lipid emulsions on cholestasis rate in comparison to pure soya bean–based lipid emulsion in neonates
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(24,109). One study investigated the difference between OO/SO
(20% ClinOleic) and SO ILE (20% Intralipid) in children with
prolonged PN (>3 months) due to short bowel syndrome, intract-
able diarrhoea, or intestinal pseudo-obstruction (24). That study
found no difference in the liver enzymes, bilirubin, and biliary acids
between groups. The more recent study investigated the difference
between multicomponent FO-containing ILE (20% SMOFlipid)
and SO ILE (20% Intralipid) during a 29-day period in children
on home PN with short bowel syndrome, intestinal pseudo-obstruc-
tion, or congenital disease of the intestinal mucosa and reported a
significant difference in the change in bilirubin levels from baseline
to day 29 between groups (109). The present study found a decrease
in the bilirubin levels in the multicomponent FO-containing group
and an increase in the SO group; however, bilirubin levels in both
groups were low and did not reach cholestatic levels (109). A recent
study examined the influence of FO ILE (10% Omegaven) versus
SO ILE (20% Intralipid) on cholestasis reversal in young infants
with prolonged PN (110). The present study included only 16
patients and found no difference in the age at which an improve-
ment in cholestasis occurred; however, only in the FO-based group
did proportion (3 out of 9) of infants recover from cholestasis while
still on PN. The present study also showed a significant decrease in
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progression in conjugated bilirubin and ALT levels in infants on FO
compared with those on SO. Moreover, this is the first study which
compared the same dose of FO-based ILE and SO-based ILE
(both groups received 1.5 g  kg1  day1).
DISCUSSION
This systematic review found a limited number of RCTs,
which evaluated the short and long-term effect of ILE on bilirubin
or liver enzyme levels. The majority of the available RCTs were
performed in premature neonates (more than 1200 infants included)
in whom ILE were administered for a short period of time. None of
the ILEs were found to be significantly more efficacious in the
prevention of cholestasis and decrease in bilirubin levels and liver
enzymes. It should, however, be noted that all studies had different
primary endpoints and did not evaluate the same parameters. Some
studies did not mention exact bilirubin or liver enzyme levels,
which prevented further analysis (102,105,106). The number of
studies in infants and children (130 infants/children included) on
long-term PN is limited. This systematic review identified only 3
RCTs (24,109,110), which all used different ILE and 1 study on
prolonged PN in neonates (108) which compared FO to SO ILE. A
study which assessed OO/SO ILE versus SO ILE found no differ-
ence in bilirubin levels (24). On the contrary, the same group of
authors found that the use of multicomponent FO-containing ILE
significantly decreased bilirubin levels (109). Both of these studies
were, however, performed in children without cholestasis, and the
bilirubin levels were not elevated even after the study. The study
performed in infants evaluated the role of FO in infants with
cholestasis and found a positive effect on the decrease in bilirubin
(110). Because all 3 RCTs used different ILE it was not possible to
perform a meta-analysis. The only study investigating prolonged
PN in neonates assessed the difference between FO and SO (used in
the same dosage—1 mg/kg) on the incidence of cholestasis (108).
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The present study terminated prematurely due to low incidence in
cholestasis in both groups; furthermore, all other liver-related
parameters did not differ between groups.
The role of a pure SO ILE on PNALD is well recognized and
because of that, expectations after the introduction of MCT- and
OO-containing ILE were high. Available evidence does not support
their superiority over solely SO for short-term use. RCTs that
evaluated the difference between SO-based and OO/SO ILE
(95–97,102,103) and MCT/SO-based ILE (105,106) found no
difference in liver function tests and bilirubin levels. Furthermore,
meta-analysis found no difference in bilirubin levels and liver
enzymes between OO/SO and SO ILE. All of these studies were
performed in premature neonates and did not evaluate the effect on
the liver as a primary outcome. There are also 2 RCTs performed in
older children; 1 study, which included children after surgery found
a decrease in liver function test in the group of children on MCT/
SO-based ILE; however, the present study included only 10% lipid
emulsions not recommended for children (111). The other study
was performed in children after bone marrow transplantation and
found no effect comparing OO/SO ILE to MCT/SO-based ILE
(112). Those studies were performed in children who had not had
gut resections and did not have severe liver disease, and therefore
evaluated only the possible hepatotoxic effect of different ILE in the
short term. OO/SO ILE, however, did not show an advantage over
SO ILE even in children on long-term PN (24). The potential
advantages of OO/SO ILE are to decrease the risks related to an
excessive intake of PUFAs, such as increased peroxidation and also
to decrease the plant sterol load, and may also be beneficial due to
naturally high vitamin E content (27,28). Clinical studies, however,
have not proven that the use of these ILE result in improvement in
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liver function compared to the historical pure SO-based ILE
(6,95,97,101,102).
Moreover, neither animal models (113) nor the observational
clinical data have demonstrated clear superiority of MCT/SO or
OO/SO ILE (24) over their SO ILE counterparts regarding preven-
tion or recovery of cholestasis or PNALD (21,114,115).
In 2005, the guidelines provided by the ESPGHAN and
ESPEN experts stated that the use of commercial lipid emulsions
based on LCT (SO or OO/SO) or physical mixtures of MCT/SO
could be considered generally safe in infants and children and that
there was currently no evidence (based on clinical outcome data)
supporting the advantage of any of the ILE that were currently
available (6). Based on the all available data, it seems that intro-
duction of MCT or OO in ILE did not significantly contribute to the
resolution or prevention of hepatotoxic effect of ILE, and that new
data support previous guidelines regarding these ILEs.
Expectations for FO-based lipid emulsions were even higher.
Good quality data are, however, lacking; there are only 2 RCTs
available which compared FO to SO ILE in neonates (108) and
infants on prolonged PN (110). Several case studies presented by
the same team reported the efficacy FO as monotherapy (at a
reduced dose—1 g/kg) in the treatment of PNALD in infants
and children (79–86). In most of the studies, a high dose of SO
emulsion was replaced by 1 g/kg of FO. Therefore, it is still not clear
whether reversal of cholestasis was due to the effect of stopping the
soya bean load or the effect of FO itself (including the high a-
tocopherol load) or both. A meta-analysis of 2 of these observa-
tional studies (80,83) showed a significant decrease in plasma
bilirubin in the children treated with pure FO ILE compared to
those treated with SO ILE (38). Recently, other teams (87) also
found a remarkable effect of FO-based ILE on severe cholestasis in
preterm infants (88). Only 2 previously mentioned RCTs compared
FO to SO, 1 in infants with cholestasis on long-term PN which
found FO to be superior in the reduction of bilirubin and ALT levels
(110) and the other in neonates without cholestasis on prolonged PN
which found no difference in the cholestasis incidence and bilirubin
levels between groups (108). The strength of both of these studies is
that both arms (experimental and control) used the same lipid dose
[1.5 mg  kg1  day1 in 1 (110) and 1 mg  kg1  day1 in the other
study (108)].
The newest ILE are multicomponent FO-containing ILE,
which could have several theoretical advantages. Their effect was
assessed by several RCTs in neonates and 1 RCT in children with
long-term PN (37,60,93,98–100,109). Although some studies
found that the use of multicomponent FO-containing lipid emul-
sions have positive effect on bilirubin levels in premature infants
and neonates, meta-analysis found no superiority of these multi-
component FO-containing ILE compared to SO ILE. Regarding
children on prolonged PN, 1 RCT found that multicomponent FO-
containing ILE led to significant decrease of total bilirubin levels
compared to SO ILE; however, in both groups bilirubin levels were
not abnormal at the end of the study (109). There are also several
nonrandomized cohort studies which found resolution of cholestasis
after multicomponent FO-containing ILE was introduced (89,90).
When interpreting these results the small sample size (8 and 9
patients) and design of the study should, however, be taken into
account. Furthermore, in children with IF the pathogenesis of liver
disease is extremely complex and intervention should not be limited
only to different ILE. There is evidence indicating that just tailoring
and adjusting PN in children on long-term PN could improve liver
disease (116), meaning that the focus should not only be on the type
of ILE.
Considering all these results it seems that addition of FO and
reduction of SO could be beneficial in reducing cholestasis in
children on long-term PN. The overall quality of the data is,TA
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however, poor and well-designed RCTs including larger numbers of
patients are lacking.
Furthermore, there are no RCTs that assess the role of ILE on
liver fibrosis with some evidence showing persistent liver fibrosis
even several years after PN discontinuation (117). A small adult
study showed histologic improvement after 4 weeks of treatment
with pure FO, with a so-called marked decrease in inflammation
and cholestasis (27). Some animal and human studies suggest that
fibrosis persists or even progresses despite normalization of cho-
lestasis markers using FO (118–122). These studies underline the
limitations of relying on cholestasis as the sole endpoint. Recently,
Mercer et al (121) blindly examined liver biopsies in 6 children with
cholestasis who were treated with FO ILE and although hyperbilir-
ubinaemia reversed in all children, there was no influence on
fibrosis in 5 of 6 children. Thus, it is still not clear whether a
decrease in bilirubin levels is a good marker for improvement of
liver damage.
Finally, when interpreting the results of this systematic
review it should be emphasized that we only examined the effect
of different ILE on cholestasis or PNALD other parameters, which
could potentially be influenced by the use of different ILE, for
example, nutritional adequacy, growth, development, nosocomial
infections, and so on were not evaluated. ILE are an important
noncarbohydrate source of energy and an integral part of paediatric
PN. Furthermore, ILE in children, particularly in infants, are the
main provider of essential fatty acids. EPA and DHA can be
synthesized from a-linolenic acid, yet the capacity of the converting
enzyme pathway is limited. Physiological DHA requirements are
highest in the perinatal period and infants are dependent on dietary
DHA intake from the mother’s milk or formula (123). Therefore,
there is a serious concern that the DHA supply in SO ILE may be
limiting for infant development. On the contrary, exclusive FO lipid
intake during the perinatal period resulted in growth retardation and
delayed psychomotor development in rats (124). Therefore, the
optimal n-3 fatty acid and FO intake (dosage and duration) in
children who depend on PN lipid delivery should be better defined,
especially in infants. Short-term studies showed that multicompo-
nent FO-containing ILE was well tolerated in premature neonates
with a modification of red blood cell phospholipid fatty acid pattern
as compared with a group receiving an SO ILE (37,98,100).Long-
term studies are, however, needed to assess the effects of prolonged
administration of different fatty acid mixtures on fatty acid
profile, growth, and neurodevelopment especially in children on
prolonged PN.
CONCLUSIONS
The ESPGHAN Committee on Nutrition (CoN) concludes
 There is no evidence of a difference in bilirubin, conjugated
bilirubin, AST, ALT, ALP, and GGT between short-term use of
OO/SO and SO ILE in infants and children (level of evidence
2a).
 There is no evidence of a difference in bilirubin, conjugated
bilirubin, AST, ALT, ALP, and GGT between short-term use of
multicomponent FO-containing ILE and SO ILE in neonates
(level of evidence 2a).
 The use of multicomponent FO-containing ILE may contribute
to a decrease in total bilirubin levels in children with IF on
prolonged PN (level of evidence 2b).
 Pure FO supply combined with a decrease or interruption of SO
ILE may contribute to cholestasis recovery in children with
PNALD (level of evidence 2b).
RECOMMENDATIONS
 Prevention and care of PNALD in children should not be focused
exclusively on parenteral ILE intake.
 Because of their high phospholipid content, 10% ILE should no
longer be used (GR B).
 Based on available evidence, the CoN cannot currently
recommend the use of any specific ILE for short-term use in
infants and children for the prevention and treatment of PNALD
(GR B).
 For children in whom long-term use of PN is expected, it appears
prudent to use multicomponent FO-containing ILE (GR C).
 The present evidence base is inadequate to determine the optimal
strategy for intravenous lipid supply in both preterm and term
infants and older children to prevent or treat liver complications.
 In particular, studies on both the prevention and treatment of
PNALD should be conducted in high-risk infants and children
who are likely to require long-term PN, and should also consider
additional extrahepatic outcomes such as growth and cognition.
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